Bovine IGFBP-6 - Ready-To-Use ELISA Kit (Colorimetric)

Name: Bovine IGFBP-6 - Ready-To-Use ELISA Kit (Colorimetric)
Brand: Novus Biologicals
SKU: NBP3-52604

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-52604

Submit a review

Product Datasheet / COA

100% Guarantee

Product Specifications
Precision
Kit Contents
Preparation & Storage
Background
Product Documents
Specific Notices

Key Product Details

Sample Type & Volume Required Per Well

Serum, plasma and other biological fluids (100 uL)

Sensitivity

0.94 ng/mL (example only; lot dependent)

Assay Range

2.5 - 160 ng/mL (example only; lot dependent)

View all IGFBP-6 ELISA Kits »

Product Specifications

Assay Type

Sandwich ELISA

Kit Type

ELISA Kit (Colorimetric)

Reactivity

Bovine

Description

The Ready-To-Use ELISA kit offers pre-diluted detection reagents and a shorter experimental time.
Assay Length: 3 hours

Precision

Intra-Assay Precision (Precision within an assay) %CV < 10 (example only; lot dependent)

Inter-Assay Precision (Precision between assays) %CV < 12 (example only; lot dependent)

Kit Contents for Bovine IGFBP-6 - Ready-To-Use ELISA Kit (Colorimetric)

Pre-coated 96T strip plate, Plate sealer for 96 wells, Standard, Standard Diluent, Detection Solution A, Detection Solution B, TMB Substrate, Stop Solution, Wash Buffer (30 x concentrate), Instruction manual

Preparation and Storage

Stability & Storage

Storage of components varies. See protocol for specific instructions.

Background: IGFBP-6

Data show that an increase in JNK activation in the presence of NFkappaB inhibition significantly increased the expression of IGFBP6. These studies provide evidence that over expression of IGFBP-6 suppresses human and murine osteoblast differentiation, that IGFBP-6 and LMP-1 physically interact, and supports the conclusion that this interaction may be functionally relevant. IGFBP-6 is the effector of tumor suppressor activity of SEMA3B. Observational study of gene-disease association. (HuGE Navigator) IGFBP-6 is translocated to the nucleus with functional consequences, and different members of the IGFBP family have specific nuclear import mechanisms. Toxic effect of TCDD on osteogenesis through altering IGFBP6 gene expression in osteoblasts is reported. p38 MAPK is involved in IGFBP-6-induced IGF-independent rhabdomyosarcoma cell migration. determination of blood levels in adult patients with severe liver disease before and after orthotopic liver transplantation. Inhibition of human osteoblast marker gene expression by retinoids is mediated in part by insulin-like growth factor binding protein-6. A close correlation exists between residues of the carboxyl-terminal domain of IGFBP6 undergoing conformational change in 15N NMR spectroscopy studies with those that disappeared or broadened upon insulin-like growth factor (IGF-II) binding. C-domain of IGFBP-6 consists of a thyroglobulin type 1 fold comprising an alpha-helix followed by a loop, a three-stranded antiparallel beta-sheet incorporating a second loop, and a disulfide-bonded flexible third loop. The expression of certain IGFBP is significantly altered in renal cell carcinoma. CCI-779 acts additively with IGFBP-6 to reduce rhabdomyosarcoma growth both in vitro and in vivo. may function as an antiproliferative molecule suppressing mitogenic effects of insulin-like growth factors on Malassez cells. The IGFBP-6 protein is synthesized as propeptides with a hydrophobic leader sequence, removal of which yields a mature protein composed of 3 recognizable domains of similar size. transgenic human IGFBP-6 mice may be considered a new tool for studies of the involvement of the brain IGF system in metabolism control and obesity.

Long Name

Insulin-like Growth Factor Binding Protein 6

Alternate Names

IGFBP6

Gene Symbol